{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:11:24Z","timestamp":1790784684511,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40262-025-01508-1","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:20:20Z","timestamp":1748636420000},"page":"925-942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"64","author":[{"given":"Theodoros","family":"Papathanasiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Kaullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Polireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Liu","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekemi","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Struemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Ferron-Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"10","key":"1508_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R Montes de Oca","year":"2021","unstructured":"Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab Mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941\u201355. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0035.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1508_CR2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187\u201399. https:\/\/doi.org\/10.2217\/imt.15.77.","journal-title":"Immunotherapy"},{"issue":"23","key":"1508_CR3","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, et al. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023;129(23):3746\u201360. https:\/\/doi.org\/10.1002\/cncr.34987.","journal-title":"Cancer"},{"issue":"10","key":"1508_CR4","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u201312. https:\/\/doi.org\/10.1016\/S2352-3026(23)00243-0.","journal-title":"Lancet Haematol."},{"key":"1508_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab Mafodotin, Bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2405090.","journal-title":"N Engl J Med"},{"key":"1508_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2403407.","journal-title":"N Engl J Med"},{"key":"1508_CR7","unstructured":"A Study of Belantamab Mafodotin monotherapy in multiple myeloma participants with normal and varying degree of impaired renal function (DREAMM12) [internet]. ClinicalTrials.gov identifier: NCT04398745. [cited 2024 July 8]. https:\/\/clinicaltrials.gov\/study\/NCT04398745. Accessed 12 Aug 2024."},{"issue":"16_suppl","key":"1508_CR8","doi-asserted-by":"publisher","first-page":"TPS8073","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8073","volume":"40","author":"M Hultcrantz","year":"2022","unstructured":"Hultcrantz M, Kleinman D, Ghataorhe P, McKeown A, He W, Ling T, et al. Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14. J Clin Oncol. 2022;40(16_suppl):TPS8073. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS8073.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1508_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-139332","volume":"136","author":"R Popat","year":"2020","unstructured":"Popat R, Nooka A, Stockerl-Goldstein K, Abonour R, Ramaekers R, Khot A, et al. DREAMM-6: safety, tolerability and clinical activity of Belantamab Mafodotin (Belamaf) in combination with bortezomib\/dexamethasone (BorDex) in relapsed\/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):19\u201320. https:\/\/doi.org\/10.1182\/blood-2020-139332.","journal-title":"Blood"},{"issue":"8","key":"1508_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/psp4.12660","volume":"10","author":"C Rathi","year":"2021","unstructured":"Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, Ferron-Brady G. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed\/refractory multiple myeloma. CPT Pharmacomet Syst Pharmacol. 2021;10(8):851\u201363. https:\/\/doi.org\/10.1002\/psp4.12660.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"Supplement 1","key":"1508_CR11","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1182\/blood-2023-178026","volume":"142","author":"G Ferron-Brady","year":"2023","unstructured":"Ferron-Brady G, Taylor A, Kaullen J, Polireddy K, McKeown A, Sule N, et al. Population pharmacokinetics (PopPK) and exposure-response (E-R) analyses for Belantamab Mafodotin monotherapy in patients with relapsed\/refractory multiple myeloma (RRMM) enrolled in DREAMM-2 and DREAMM-3. Blood. 2023;142(Supplement 1):6730. https:\/\/doi.org\/10.1182\/blood-2023-178026.","journal-title":"Blood"},{"key":"1508_CR12","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2022. https:\/\/www.R-project.org\/. Accessed 02 Sept 2024."},{"issue":"14_suppl","key":"1508_CR13","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1200\/jco.2004.22.90140.6051","volume":"22","author":"H Patel","year":"2004","unstructured":"Patel H, Egorin MJ, Remick SC, Mulkerin D, Takimoto CHM, Doroshow JH, et al. Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): implications for chemotherapy dosing. J Clin Oncol. 2004;22(14_suppl):6051. https:\/\/doi.org\/10.1200\/jco.2004.22.90140.6051.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1508_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/a:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138. https:\/\/doi.org\/10.1023\/a:1011970125687.","journal-title":"Pharm Res"},{"key":"1508_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/antib10020020","author":"I Mahmood","year":"2021","unstructured":"Mahmood I. Clinical pharmacology of antibody-drug conjugates. Antibodies (Basel). 2021. https:\/\/doi.org\/10.3390\/antib10020020.","journal-title":"Antibodies (Basel)."},{"key":"1508_CR16","unstructured":"GSK UK. BLENREP 100 mg powder for concentrate for solution for infusion. 2023. https:\/\/www.medicines.org.uk\/emc\/product\/100782\/smpc#gref. Accessed 09 Sept 2024."},{"issue":"8","key":"1508_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493\u2013507. https:\/\/doi.org\/10.2165\/11531280-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1508_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bcp.15990","volume":"90","author":"S Armani","year":"2024","unstructured":"Armani S, Geier A, Forst T, Merle U, Alpers DH, Lunnon MW. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug-drug interactions. Br J Clin Pharmacol. 2024;90(4):942\u201358. https:\/\/doi.org\/10.1111\/bcp.15990.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1508_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/psp4.12561","volume":"9","author":"JB Fau","year":"2020","unstructured":"Fau JB, El-Cheikh R, Brillac C, Koiwai K, Mace N, Campana F, et al. Drug-disease interaction and time-dependent population pharmacokinetics of isatuximab in relapsed\/refractory multiple myeloma patients. CPT Pharmacomet Syst Pharmacol. 2020;9(11):649\u201358. https:\/\/doi.org\/10.1002\/psp4.12561.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"1508_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, et al. Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1. Target Oncol. 2023;18(5):667\u201384. https:\/\/doi.org\/10.1007\/s11523-023-00989-z.","journal-title":"Target Oncol"},{"issue":"1","key":"1508_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13676","volume":"17","author":"JR Proctor","year":"2024","unstructured":"Proctor JR, Wong H. Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: a comprehensive review of the current literature. Clin Transl Sci. 2024;17(1): e13676. https:\/\/doi.org\/10.1111\/cts.13676.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"1508_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40262-018-0694-x","volume":"58","author":"JC Masters","year":"2019","unstructured":"Masters JC, Barry E, Knight B. Population pharmacokinetics of gemtuzumab ozogamicin in pediatric patients with relapsed or refractory acute myeloid leukemia. Clin Pharmacokinet. 2019;58(2):271\u201382. https:\/\/doi.org\/10.1007\/s40262-018-0694-x.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1508_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40262-024-01366-3","volume":"63","author":"AG Sathe","year":"2024","unstructured":"Sathe AG, Singh I, Singh P, Diderichsen PM, Wang X, Chang P, et al. Population pharmacokinetics of sacituzumab govitecan in patients with metastatic triple-negative breast cancer and other solid tumors. Clin Pharmacokinet. 2024;63(5):669\u201381. https:\/\/doi.org\/10.1007\/s40262-024-01366-3.","journal-title":"Clin Pharmacokinet"},{"key":"1508_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01386-z","author":"JH Wu","year":"2024","unstructured":"Wu JH, Pennesi E, Bautista F, Garrett M, Fukuhara K, Brivio E, et al. Population pharmacokinetics of inotuzumab ozogamicin in pediatric relapsed\/refractory B-Cell precursor acute lymphoblastic leukemia: results of study ITCC-059. Clin Pharmacokinet. 2024. https:\/\/doi.org\/10.1007\/s40262-024-01386-z.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1508_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cpt.656","volume":"101","author":"C Liu","year":"2017","unstructured":"Liu C, Yu J, Li H, Liu J, Xu Y, Song P, et al. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther. 2017;101(5):657\u201366. https:\/\/doi.org\/10.1002\/cpt.656.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1508_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/psp4.12477","volume":"9","author":"K Sanghavi","year":"2020","unstructured":"Sanghavi K, Zhang J, Zhao X, Feng Y, Statkevich P, Sheng J, et al. Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors. CPT Pharmacomet Syst Pharmacol. 2020;9(1):29\u201339. https:\/\/doi.org\/10.1002\/psp4.12477.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"1508_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/psp4.12406","volume":"8","author":"JJ Wilkins","year":"2019","unstructured":"Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, et al. Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in merkel cell carcinoma and urothelial carcinoma. CPT Pharmacomet Syst Pharmacol. 2019;8(6):415\u201327. https:\/\/doi.org\/10.1002\/psp4.12406.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"1508_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00280-019-03821-6","volume":"84","author":"E Wang","year":"2019","unstructured":"Wang E, Song F, Paulus JK, Hackenyos D, Mathew P. Qualitative and quantitative variations in liver function thresholds among clinical trials in cancer: a need for harmonization. Cancer Chemother Pharmacol. 2019;84(1):213\u20136. https:\/\/doi.org\/10.1007\/s00280-019-03821-6.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01508-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01508-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01508-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T13:42:32Z","timestamp":1749649352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01508-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1508"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01508-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"13 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by GSK (studies 205678, 207495, 207497, 207503, 207499, 209626, 209628). Drug linker technology was licensed from Seagen Inc.; monoclonal antibodies were produced using POTELLIGENT Technology licensed from BioWa.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Theodoros Papathanasiou, Xi Chen, Yu Liu Ho, Herbert Struemper, Fernando Carre\u00f1o, and Geraldine Ferron-Brady are employees of and hold financial equities in GSK. Josh Kaullen, Kishore Polireddy, and Adekemi Taylor are employees of Certara and provide consultancy to GSK. Josh Kaullen and Adekemi Taylor are also stockholders of Certara.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Protocols and informed consent forms were reviewed and approved by institutional review boards\/independent ethics committees according to local guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients in each study provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors were involved in manuscript writing, review, and editing and read and approved the final manuscript. Theodoros Papathanasiou, Xi Chen, Yu Liu Ho, Adekemi Taylor, Herbert Struemper, Fernando Carre\u00f1o, and Geraldine Ferron-Brady contributed to study conception and design. Xi Chen, Yu Liu Ho, Herbert Struemper, Fernando Carre\u00f1o, and Geraldine Ferron-Brady were responsible for data acquisition. Josh Kaullen, Kishore Polireddy, and Adekemi Taylor analyzed the data. All authors were involved in data interpretation.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"GSK makes available anonymized individual participant data and associated documents from interventional clinical studies that evaluate medicines, upon approval of proposals submitted to .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Available upon reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}